½ÃÀ庸°í¼­
»óǰÄÚµå
1517299

¼¼°èÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå ±Ô¸ð Á¶»ç : Á¦Ç°º°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Å뺰, ¿ëµµº°, Áö¿ªº° ¿¹Ãø(2022-2032³â)

Global Anti-Mullerian Hormone Test Market Size Study, by Product, by End-User, by Distribution, by Use, and Regional Forecasts 2022-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀåÀº 2023³â ¾à 2¾ï 7,426¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024³âºÎÅÍ 2032³â±îÁö 11.46% ÀÌ»óÀÇ °Ç°­ÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

AMH °Ë»ç´Â »ý½Ä ÀÇÇп¡¼­ Áß¿äÇÑ Áø´Ü µµ±¸·Î ³­¼Ò ¿¹ºñ·Â, ³­ÀÚÀÇ ¾ç, ÀáÀçÀû Àӽа¡´É¼º¿¡ ´ëÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS), ¿ø¹ß¼º ³­¼Ò ±â´É ºÎÀü(POI) µîÀÇ »óŸ¦ Æò°¡ÇÏ´Â µ¥ ƯÈ÷ À¯¿ëÇϸç, ü¿Ü¼öÁ¤(IVF) °úÁ¤¿¡¼­ ¾à¹° Åõ¿© ¹× ³­¼Ò ¹ÝÀÀÀ» ¿¹ÃøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. »ý½Ä °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÇ Áõ°¡, Á¶±â ¹× Á¤È®ÇÑ ºÒÀÓ Áø´ÜÀÇ Çʿ伺, ù ÀӽŠ¿¬·ÉÀÇ Áõ°¡ µîÀÌ AMH °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±â¼ú ¹ßÀü°ú ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î ÀÎÇØ Á¢±Ù¼º°ú ±¸¸Å ¿ëÀ̼ºÀÌ ´õ¿í Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÀúÀÚ¿ø ȯ°æ¿¡¼­ÀÇ Á¦ÇÑµÈ Àνİú ³ôÀº °Ë»ç ºñ¿ë, Ç¥ÁØÈ­µÈ °Ë»ç ÇÁ·ÎÅäÄÝÀÇ Çʿ伺°ú ÇÔ²² ½ÃÀå ħÅõ¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AMH ¼öÄ¡¿Í °ü·Ã °¡ÀÓ·Â ¿äÀÎÀ» ÇØ¼®Çϱâ À§ÇÑ ±â¼ú ÅëÇÕÀº Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

POC(Point-of-Care) °Ë»ç´Â ÀÓ»ó ÇöÀå¿¡¼­ ½Å¼ÓÇÑ ÀÇ»ç°áÁ¤À» °¡´ÉÇÏ°Ô Çϰí Áï°¢ÀûÀÎ °á°ú¸¦ ¾òÀ» ¼ö Àֱ⠶§¹®¿¡ Á¡Á¡ ´õ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Å×½ºÆ®´Â »ç¿ë ÆíÀǼº°ú ºü¸¥ °á°ú¸¦ Á¦°øÇϵµ·Ï ¼³°èµÇ¾î ºÒÀÓ Æò°¡ÀÇ °£¼ÒÈ­°¡ ÇÊ¿äÇÑ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô ÀÌ»óÀûÀÔ´Ï´Ù. ÀÚ°¡ °Ë»ç ŰƮ´Â ÇÁ¶óÀ̹ö½Ã¿Í Æí¸®ÇÔÀ» ¿øÇÏ´Â °³Àο¡°Ô ÀûÇÕÇϸç, Áý¿¡¼­ ºÒÀÓ °Ë»çÀÇ Ãʱ⠴ܰ踦 ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. »ó¾÷¿ë ½ÇÇè½ÇÀº ÀÓ»óÀÇ¿Í Àü¹®°¡¿¡°Ô °í±Þ Áø´Ü µµ±¸¸¦ Á¦°øÇÏ¿© ´ë·® °Ë»çÀÇ È¿À²¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇÕ´Ï´Ù. ¿¬±¸ °³¹ß(R&D) ±â°üÀº ºÒÀÓ Ä¡·á ¹× »ý½Ä ÀÇÇÐ ¿¬±¸¸¦ ÁøÇàÇϱâ À§ÇØ °í°¨µµ °Ë»ç¸¦ ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. À¯Åë °æ·Î°¡ ÁøÈ­Çϰí ÀÖÀ¸¸ç, Æí¸®ÇÔ°ú ÇÁ¶óÀ̹ö½Ã¸¦ ¿øÇÏ´Â ¼ÒºñÀÚµéÀº »ó¼¼ÇÑ Á¦Ç° Á¤º¸¿Í »ç¿ëÀÚ ¸®ºä¸¦ Á¦°øÇÏ´Â ¿Â¶óÀÎ Ç÷§ÆûÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù.

Àΰ£ÀÇ °æ¿ì, AMH °Ë»ç´Â ³­¼Ò ¿¹ºñ·Â°ú °¡ÀÓ·ÂÀ» Æò°¡ÇÏ´Â °Ë»ç·Î ºÒÀÓ Ä¡·á¿Í »ý½Ä °Ç°­ Æò°¡¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ºñÀΰ£ ¿µÀå·ù¿¡¼­´Â º¸È£ Ȱµ¿°ú ¹ø½Ä ÇÁ·Î±×·¥ °ü¸®¿¡ µµ¿òÀÌ µÇ¸ç, ¹ø½Ä °¡´É¼º¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå¿¡¼­ ¼öÀÍ Ãø¸é¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ÀÎ½Ä °³¼± µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ¼±ÁøÀûÀÎ ÀÇ·á ÀÎÇÁ¶ó¿Í ´ë±Ô¸ð R&D ÅõÀÚ·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, À¯·´ ½ÃÀåÀº ÇコÄɾî ÀÎÇÁ¶ó¿Í Á¤Ã¥ °­È­¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ÁÖ¿ä ¿ä¾à

  • Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
  • Áö¿ªº° °³¿ä
  • ºÎ¹®º° °³¿ä
    • Á¦Ç°º°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • À¯Å뺰
    • ¿ëµµº°
  • ÁÖ¿ä µ¿Çâ
  • °æ±âÈÄÅðÀÇ ¿µÇâ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦2Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå Á¤ÀÇ¿Í Á¶»ç °¡Á¤

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ
  • Á¶»ç °¡Á¤
    • Æ÷ÇÔ°ú Á¦¿Ü
    • Á¦ÇÑ»çÇ×
    • °ø±ÞÃø ºÐ¼®
      • ÀÔ¼ö °¡´É¼º
      • ÀÎÇÁ¶ó
      • ±ÔÁ¦ ȯ°æ
      • ½ÃÀå °æÀï
      • °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
    • ¼ö¿äÃø ºÐ¼®
      • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
      • ±â¼úÀÇ Áøº¸
      • ģȯ°æ
      • ¼ÒºñÀÚ Àǽİú ¼ö¿ë
  • Á¶»ç ¹æ¹ý
  • Á¶»ç ´ë»ó ¿¬µµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • »ý½Ä¿¡ °üÇÑ °Ç°­ ¹®Á¦¿¡ ´ëÇÑ Àνİú ¹ß»ý·ü »ó½Â
    • ¼öÅ °¡´É¼º Æò°¡¸¦ ÇÊ¿ä·Î Çϴ ùȸ ÀӽŠ¿¬·É Áõ°¡
    • Áø´Ü ±â¼úÀÇ Áøº¸
  • ½ÃÀå °úÁ¦
    • ÀúÀÚ¿ø ȯ°æÀÇ ÇÑÁ¤µÈ ÀνÄ
    • °íºñ¿ë°ú Ç¥ÁØÈ­µÈ °Ë»ç ÇÁ·ÎÅäÄÝÀÇ Çʿ伺
  • ½ÃÀå ±âȸ
    • AMHÄ¡¸¦ ÇØ¼®Çϱâ À§ÇÑ ±â¼ú ÅëÇÕ
    • ¼¼°èÀÇ ÇコÄɾî ÀÎÇÁ¶ó È®´ë

Á¦4Àå ¼¼°èÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå, »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
    • Porter's Five Forces ¸ðµ¨·ÎÀÇ ¹Ì·¡ÁöÇâÀû Á¢±Ù¹ý
    • Porter's Five ForcesÀÇ ¿µÇ⠺м®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦5Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Àå Á¦Ç°º°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • POC °Ë»ç
    • ¼¿ÇÁ üũ ŰƮ

Á¦6Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • »ó¾÷ ½ÇÇè½Ç
    • ¿¬±¸°³¹ß

Á¦7Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : À¯Å뺰, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • ¿ÀÇÁ¶óÀΠä³Î
    • ¿Â¶óÀΠä³Î

Á¦8Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â

  • ºÎ¹® ´ë½Ãº¸µå
  • Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå : ¸ÅÃâ µ¿Ç⠺м®, 2022³â¡¤2032³â
    • Àΰ£
    • ºñÀΰ£ ¿µÀå·ù

Á¦9Àå Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ¼¼°è ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â

  • ºÏ¹ÌÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ¹Ì±¹ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ij³ª´ÙÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
  • À¯·´ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ¿µ±¹ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • µ¶ÀÏÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ÇÁ¶û½ºÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ½ºÆäÀÎÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ÀÌÅ»¸®¾ÆÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ±âŸ À¯·´ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • Áß±¹ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ÀεµÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ÀϺ»ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • È£ÁÖ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • Çѱ¹ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ºê¶óÁúÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ¸ß½ÃÄÚÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • »ç¿ìµð¾Æ¶óºñ¾ÆÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ç׹흰üÈ£¸£¸ó(AMH) °Ë»ç ½ÃÀå

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Abbexa Limited
    • Abcam PLC
    • Ansh Labs LLC
    • Athenese-Dx
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • bioMerieux S.A.
    • BioVendor-Laboratorni Medicina A.S.
    • Chengdu VACURE Biotechnology Co., Ltd.
    • CTK Biotech, Inc.
    • Cusabio Technology LLC
    • Eagle Biosciences, Inc.
    • Elabscience Bionovation Inc.
    • Epitope Diagnostics, Inc.
    • F. Hoffmann-La Roche Ltd.

Á¦11Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
ksm 24.08.02

Global Anti-Mullerian Hormone (AMH) Test Market is valued at approximately USD 274.26 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.46% over the forecast period 2024-2032. AMH tests are crucial diagnostic tools in reproductive medicine, providing essential information about ovarian reserve, egg quantity, and potential fertility. These tests are particularly valuable in assessing conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) and are instrumental in in vitro fertilization (IVF) procedures for medication dosing and predicting ovarian response. The growing awareness of reproductive health issues, the necessity for early and precise fertility diagnosis, and the increasing age of first-time pregnancies drive the demand for AMH tests. Technological advancements and expanding healthcare infrastructure further enhance accessibility and affordability. However, the limited awareness in low-resource settings and the high cost of tests, coupled with the need for standardized testing protocols, present challenges to market penetration. Moreover, technological integration for interpreting AMH levels and related fertility factors offers significant growth opportunities.

Point-of-care (POC) testing is increasingly preferred for its immediate results, enabling swift decision-making in clinical practice. These tests are designed for ease of use and rapid results, ideal for healthcare providers needing to streamline fertility evaluations. Self-check kits cater to individuals seeking privacy and convenience, providing an initial step in fertility investigation from home. Commercial labs serve clinicians and specialists with advanced diagnostic tools, ensuring efficiency and reliability for high-volume testing. Research and development (R&D) institutions demand high-sensitivity tests for advancing fertility and reproductive health research. The distribution channels are evolving, with a growing preference for online platforms that offer detailed product information and user reviews, catering to consumers seeking convenience and privacy.

In humans, AMH tests assess ovarian reserve and fertility potential, crucial for fertility treatments and reproductive health evaluations. In non-human primates, these tests assist in conservation efforts and breeding program management, providing insights into reproductive potential.

The key regions considered for the global Anti-Mullerian Hormone (AMH) Test Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific is a dominating region in the Anti-Mullerian Hormone (AMH) Test Market in terms of revenue. The market growth in the region is being attributed to factors including increasing healthcare expenditures and awareness. Also, the region lead with advanced healthcare infrastructure and significant R&D investments. Whereas, the market in Europe is anticipated to grow at the fastest rate over the forecast period fueled by enhancing healthcare infrastructures and policies.

Major market players included in this report are:

  • Abbexa Limited
  • Abcam PLC
  • Ansh Labs LLC
  • Athenese-Dx
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux S.A.
  • BioVendor - Laboratorni Medicina A.S.
  • Chengdu VACURE Biotechnology Co., Ltd.
  • CTK Biotech, Inc.
  • Cusabio Technology LLC
  • Eagle Biosciences, Inc.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.

The detailed segments and sub-segment of the market are explained below:

By Product:

  • POC Testing
  • Self-check Kits

By End-User:

  • Commercial Labs
  • Research & Development

By Distribution:

  • Offline Channels
  • Online Channels

By Use:

  • Human
  • Non-Human Primate

By Region:

North America:

  • U.S.
  • Canada

Europe:

  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE

Asia Pacific:

  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC

Latin America:

  • Brazil
  • Mexico

Middle East & Africa:

  • Saudi Arabia
  • South Africa
  • RoMEA

Years considered for the study are as follows:

  • Historical year - 2022
  • Base year - 2023
  • Forecast period - 2024 to 2032

Key Takeaways:

  • Market Estimates & Forecast for 10 years from 2022 to 2032.
  • Annualized revenues and regional level analysis for each market segment.
  • Detailed analysis of geographical landscape with Country level analysis of major regions.
  • Competitive landscape with information on major players in the market.
  • Analysis of key business strategies and recommendations on future market approach.
  • Analysis of competitive structure of the market.
  • Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Anti-Mullerian Hormone (AMH) Test Market Executive Summary

  • 1.1. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecast (2022-2032)
  • 1.2. Regional Summary
  • 1.3. Segmental Summary
    • 1.3.1. By Product
    • 1.3.2. By End-User
    • 1.3.3. By Distribution
    • 1.3.4. By Use
  • 1.4. Key Trends
  • 1.5. Recession Impact
  • 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Anti-Mullerian Hormone (AMH) Test Market Definition and Research Assumptions

  • 2.1. Research Objective
  • 2.2. Market Definition
  • 2.3. Research Assumptions
    • 2.3.1. Inclusion & Exclusion
    • 2.3.2. Limitations
    • 2.3.3. Supply Side Analysis
      • 2.3.3.1. Availability
      • 2.3.3.2. Infrastructure
      • 2.3.3.3. Regulatory Environment
      • 2.3.3.4. Market Competition
      • 2.3.3.5. Economic Viability (Consumer's Perspective)
    • 2.3.4. Demand Side Analysis
      • 2.3.4.1. Regulatory frameworks
      • 2.3.4.2. Technological Advancements
      • 2.3.4.3. Environmental Considerations
      • 2.3.4.4. Consumer Awareness & Acceptance
  • 2.4. Estimation Methodology
  • 2.5. Years Considered for the Study
  • 2.6. Currency Conversion Rates

Chapter 3. Global Anti-Mullerian Hormone (AMH) Test Market Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Rising awareness and incidence of reproductive health issues
    • 3.1.2. Increasing age of first-time pregnancies necessitating fertility assessments
    • 3.1.3. Advancements in diagnostic technologies
  • 3.2. Market Challenges
    • 3.2.1. Limited awareness in low-resource settings
    • 3.2.2. High cost and need for standardized testing protocols
  • 3.3. Market Opportunities
    • 3.3.1. Technological integration for interpreting AMH levels
    • 3.3.2. Expansion of healthcare infrastructure globally

Chapter 4. Global Anti-Mullerian Hormone (AMH) Test Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model
    • 4.1.7. Porter's 5 Force Impact Analysis
  • 4.2. PESTEL Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
    • 4.2.5. Environmental
    • 4.2.6. Legal
  • 4.3. Top investment opportunity
  • 4.4. Top winning strategies
  • 4.5. Disruptive Trends
  • 4.6. Industry Expert Perspective
  • 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Product 2022-2032

  • 5.1. Segment Dashboard
  • 5.2. Global Anti-Mullerian Hormone (AMH) Test Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 5.2.1. POC Testing
    • 5.2.2. Self-check Kits

Chapter 6. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by End-User 2022-2032

  • 6.1. Segment Dashboard
  • 6.2. Global Anti-Mullerian Hormone (AMH) Test Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 6.2.1. Commercial Labs
    • 6.2.2. Research & Development

Chapter 7. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Distribution 2022-2032

  • 7.1. Segment Dashboard
  • 7.2. Global Anti-Mullerian Hormone (AMH) Test Market: Distribution Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 7.2.1. Offline Channels
    • 7.2.2. Online Channels

Chapter 8. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Use 2022-2032

  • 8.1. Segment Dashboard
  • 8.2. Global Anti-Mullerian Hormone (AMH) Test Market: Use Revenue Trend Analysis, 2022 & 2032 (USD Million)
    • 8.2.1. Human
    • 8.2.2. Non-Human Primate

Chapter 9. Global Anti-Mullerian Hormone (AMH) Test Market Size & Forecasts by Region 2022-2032

  • 9.1. North America Anti-Mullerian Hormone (AMH) Test Market
    • 9.1.1. U.S. Anti-Mullerian Hormone (AMH) Test Market
      • 9.1.1.1. Product breakdown size & forecasts, 2022-2032
      • 9.1.1.2. End-User breakdown size & forecasts, 2022-2032
      • 9.1.1.3. Distribution breakdown size & forecasts, 2022-2032
      • 9.1.1.4. Use breakdown size & forecasts, 2022-2032
    • 9.1.2. Canada Anti-Mullerian Hormone (AMH) Test Market
  • 9.2. Europe Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.1. U.K. Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.2. Germany Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.3. France Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.4. Spain Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.5. Italy Anti-Mullerian Hormone (AMH) Test Market
    • 9.2.6. Rest of Europe Anti-Mullerian Hormone (AMH) Test Market
  • 9.3. Asia-Pacific Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.1. China Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.2. India Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.3. Japan Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.4. Australia Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.5. South Korea Anti-Mullerian Hormone (AMH) Test Market
    • 9.3.6. Rest of Asia Pacific Anti-Mullerian Hormone (AMH) Test Market
  • 9.4. Latin America Anti-Mullerian Hormone (AMH) Test Market
    • 9.4.1. Brazil Anti-Mullerian Hormone (AMH) Test Market
    • 9.4.2. Mexico Anti-Mullerian Hormone (AMH) Test Market
    • 9.4.3. Rest of Latin America Anti-Mullerian Hormone (AMH) Test Market
  • 9.5. Middle East & Africa Anti-Mullerian Hormone (AMH) Test Market
    • 9.5.1. Saudi Arabia Anti-Mullerian Hormone (AMH) Test Market
    • 9.5.2. South Africa Anti-Mullerian Hormone (AMH) Test Market
    • 9.5.3. Rest of Middle East & Africa Anti-Mullerian Hormone (AMH) Test Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Abbexa Limited
    • 10.3.2. Abcam PLC
    • 10.3.3. Ansh Labs LLC
    • 10.3.4. Athenese-Dx
    • 10.3.5. Bio-Rad Laboratories, Inc.
    • 10.3.6. Bio-Techne Corporation
    • 10.3.7. bioMerieux S.A.
    • 10.3.8. BioVendor - Laboratorni Medicina A.S.
    • 10.3.9. Chengdu VACURE Biotechnology Co., Ltd.
    • 10.3.10. CTK Biotech, Inc.
    • 10.3.11. Cusabio Technology LLC
    • 10.3.12. Eagle Biosciences, Inc.
    • 10.3.13. Elabscience Bionovation Inc.
    • 10.3.14. Epitope Diagnostics, Inc.
    • 10.3.15. F. Hoffmann-La Roche Ltd.

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦